Clinical medicine profile
Faropenem
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Hypersensitivity to the active substance or excipients.
- Additional absolute contraindications are indication- and product-specific — consult SmPC.
Precautions
- Obtain allergy and medication history.
- Adjust for renal/hepatic impairment, pregnancy, lactation, extremes of age and interacting drugs.
- Use the lowest effective dose for the shortest appropriate duration.
- Monitor for expected class adverse effects.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- Community-acquired pneumonia, bacterial sinusitis, chronic bronchitis and skin infections.
- Clinical selection for Faropenem should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: Therapeutic agent (verify pharmacological class).
- Confirm site-specific dose, duration and monitoring before prescribing.
Adverse effects
- Shock, pseudoanaphylactic symptoms (e.g. wheezing, breathing problems), dizziness, feeling a need to evacuate the bowel, tinnitus, sweating, flushing of the whole body, vascular edema, hypotension, renal impairment, pseudomembranous colitis, Stevens-Johnson syndrome, Lyell syndrome, pneumonia, pyrexia, cough, hepatic disorders.
- Agranulocytosis, triated muscle softening, muscular pain, feeling of exhaustion, increase, hypersensitivity reactions, vitamin deficiency, symptoms of vitamin K deficiency, low prothrombin and tendency of hemorrhage.
- Symptoms of vitamin B-group deficiency.
- GIT disorders.
- Burning sensation, headache, dizziness, drowsiness, edema, dryness of the mouth and lips, change in nail color, and a washed-out feeling.
Drug interactions
Open multi-drug checker ↗- An orally-active penem group beta-lactam antibiotic that is resistant to some forms of extended-spectrum beta-lactamase.
- An orally-active penem group beta-lactam antibiotic that is resistant to some forms of extended-spectrum beta-lactamase.
Mechanism & disposition
Inhibits synthesis of bacterial cell wall, causing cell death, hence bactericidal.
Read complete mechanism
Inhibits synthesis of bacterial cell wall, causing cell death, hence bactericidal. Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.